We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Chinese drugmakers Sinovac Biotech and CanSino Biologics yesterday began separate late-stage trials of their COVID-19 vaccines in Turkey and Pakistan. Read More
New York biotech Codagenix announced Tuesday that the Serum Institute of India has begun manufacturing its intranasal COVID-19 vaccine candidate, CDX-005. Read More
The National Institutes of Health (NIH) yesterday announced the expansion of two late-stage trials of convalescent plasma in the wake of the FDA’s Emergency Use Authorization (EUA) for the investigational COVID-19 treatment. Read More
Gary Kobinger, the leader of the Canadian research team that developed a highly effective Ebola vaccine, has stepped down from Canada’s COVID-19 vaccine task force, calling for greater transparency from the group. Read More
The FDA’s planned guidance on Emergency Use Authorization (EUA) of COVID-19 vaccines may be released as soon as this week and could include standards making an EUA unlikely before the Nov. 3 presidential election. Read More
Merck said its blockbuster cancer drug Keytruda (pembrolizumab) doubled patients’ five-year survival rate compared to chemotherapy in a late-stage trial as a first-line treatment for metastatic nonsmall-cell lung cancer (NSCLC). Read More
Prominent medical journal The Lancet has tightened its publishing requirements for research papers in response to an embarrassing retraction of a study based on questionable data from multiple trials. The journal said it will now require stronger data reviews for papers based on large, real-world datasets. Read More
AstraZeneca has released the trial protocols for the late-stage study of its coronavirus vaccine candidate, AZD1222, amid mounting calls for transparency as its investigation into an adverse event continues. Read More
A separate phase 3 trial previously found that the rheumatoid arthritis drug failed to provide a benefit for hospitalized COVID-19 patients with severe pneumonia. Read More
Roche’s late-stage COVID-19 trial of Actemra (tocilizumab) showed the rheumatoid arthritis drug reduced the number of coronavirus patients who progressed to mechanical ventilation, suggesting it might be of benefit as a coronavirus treatment although the drug did not meaningfully lower mortality rates. Read More